Compared side by side

Thymosin Alpha-1 vs LL-37: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both work on the immune system, in different ways: thymosin alpha-1 is a thymic peptide that helps T-cells mature and raises natural killer cell activity, and LL-37 is the body’s own antimicrobial peptide, which in lab studies kills bacteria, fungi and some viruses. Thymosin alpha-1 is a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US; injected LL-37 hasn’t been studied in people. Thymosin alpha-1 is taken twice a week, LL-37 daily or every other day in short cycles.

Side by side

ComparedThymosin Alpha-1LL-37
CategoryHealing & recoveryHealing & recovery
Also known asTα1, Thymalfasin, ZadaxinCathelicidin, hCAP-18, CAP-18
What it isA naturally occurring thymic peptide that fine-tunes the immune system: it helps T-cells mature and raises natural killer cell activity.Your body's own antimicrobial peptide.
How it worksNaturally occurring thymic peptide that modulates immune function. It stimulates T-cell maturation and NK cell activity, and has antiviral and anti-tumor effects; the anti-tumor work is mostly in cells and animals, and human results are mixed.Human antimicrobial peptide with broad-spectrum antimicrobial activity. In lab and animal studies it modulates innate immunity, breaks up biofilms and promotes wound healing; it can be anti- or pro-inflammatory depending on context.
Commonly reportedFewer or shorter colds over a season, with little to feel day to day. It's a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US, and trial results are mixed.Noticeable injection-site redness or itching, and for some a flu-like, achy feeling in the first days. As a drug it has only been tested as a topical treatment for leg and foot ulcers, with mixed results; injected LL-37 hasn't been studied in people.
Studied rangeResearch range: 1–1.6 mg. Studied in research — not a recommendation.Research range: 100–300 mcg. Studied in research — not a recommendation.
How often2x/weekDaily or EOD
Half-life~2 hours (Zadaxin label, after a SubQ dose)Unknown in humans (short; broken down by proteases)
RouteSubQ injectionSubQ injection
Typical runCommunity cycles typically run 4–6 weeks, 2x/week, or as needed for immune support. The hepatitis B trials ran far longer: 1.6 mg twice a week for 26 or 52 weeks (Chien 1998).Short cycles of 2–4 weeks due to limited data. Conservative approach advised.
EvidenceEstablished: clinical trials or FDA-approved use existsEmerging: primarily preclinical / limited human data
Common side effectsInjection site reaction, fatigue, mild flu-like symptomsInjection site pain, redness, mild systemic inflammation

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Taking Thymosin Alpha-1 or LL-37? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Thymosin Alpha-1

  • Day 1–7 Your immune system is getting instructions
  • Day 7–14 The immune side is ramping up
  • Day 14–28 Where a common cycle ends

Every card for Thymosin Alpha-1, with its sources

LL-37

  • Day 1–7 Some feel a flu-like wave early
  • Day 7–21 Weeks 1 to 3: check what changed
  • Day 21–28 Cycle wrap-up — time to assess

Every card for LL-37, with its sources

Together or one or the other

Thymosin Alpha-1 and LL-37 are a common stack: each lists the other among its common stacks.

Community · LL-37

An immune-support trio

Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.

Questions people ask

How long do Thymosin Alpha-1 and LL-37 last?

The half-life of Thymosin Alpha-1 is ~2 hours (Zadaxin label, after a SubQ dose). The half-life of LL-37 is unknown in humans (short; broken down by proteases).

How often are Thymosin Alpha-1 and LL-37 taken?

Thymosin Alpha-1: 2x/week. Route: SubQ injection. LL-37: daily or EOD. Route: SubQ injection.

How are Thymosin Alpha-1 and LL-37 dosed in research?

The research range for Thymosin Alpha-1 is 1–1.6 mg. The research range for LL-37 is 100–300 mcg. Studied in research — not a recommendation.

What are the common side effects of Thymosin Alpha-1 and LL-37?

For Thymosin Alpha-1, the library lists: injection site reaction, fatigue, mild flu-like symptoms. For LL-37: injection site pain, redness, mild systemic inflammation.

Are Thymosin Alpha-1 and LL-37 taken together?

Thymosin Alpha-1 and LL-37 are a common stack: each lists the other among its common stacks. Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.

Each one in full

Track it in the app

PepVault for iPhone

Taking Thymosin Alpha-1 or LL-37? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo